Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 17, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

March 1, 2027

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG

FOLFOX

oxaliplatin 85mg/m2 + leucovorin 400mg/m2 + 5-fu 400mg/m2 + 5-fu 2400mg/m2 46h iv.drip Q3W

DRUG

Atezolizumab & Bevacizumab

Atezolizumab 1200mg iv.drip + Bevacizumab 15mg/kg iv.drip Q3w

Trial Locations (1)

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER